Radiofrequency ablation for XXXX : outcomes, effects on survival, and prognostic factors.

@entity1 @entity5 @entity1149 @entity2 @entity14
PURPOSE: We aimed to evaluate the survival benefit achieved with radiofrequency (RF) ablation of primary and metastatic @entity2 and determine significant prognostic factors for recurrence-free survival. METHODS: Forty-nine @entity1 with @entity2 (10 primary and 39 metastatic) underwent computed tomography-guided percutaneous RF ablation between June 2005 and October 2013. A total of 112 @entity5 (101 metastatic and 11 primary @entity1149 ) were treated with RF ablation. @entity5 diameter ranged from 0.6 to 4 cm (median 1.5 cm). Effectiveness of treatment, complications, and survival were analyzed. RESULTS: Primary success rate was 79.5% and local @entity5 progression occurred in 23 @entity5 . Among @entity5 showing progression, 10 were re-treated with RF ablation and secondary success rate was 87.5%. One-, two-, and three-year overall survival rates of 10 @entity1 with primary @entity2 were 100%, 86%, and 43%, respectively. One-, two-, three-, four-, and five-year overall survival rates for 39 @entity1 with metastatic @entity2 were 90%, 73%, 59%, 55%, and 38%, respectively. One-, two-, three-, and four-year overall survival rates for 16 @entity1 with @entity14 were 94%, 80%, 68%, and 23%, respectively. Complications occurred in 30 sessions (24.6%). Pneumothorax occurred in 19 sessions with seven requiring image-guided percutaneous chest tube drainage. @entity5 status (solitary or multiple) and presence of extrapulmonary metastasis at initial RF ablation were significant prognostic factors in terms of recurrence-free survival. CONCLUSION: RF ablation is a safe and effective treatment with a survival benefit for selected @entity1 with primary and @entity2 .
